Skip to main content

HALO

Stock
Health Care
Biotechnology

Performance overview

HALO Price
Price Chart

Forward-looking statistics

Beta
0.91
Risk
39.16%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Company info

SectorHealth Care
IndustryBiotechnology
Employees412
Market cap$6.5B

Fundamentals

Enterprise value$7.2B
Revenue$1.1B
Revenue per employee
Profit margin44.76%
Debt to equity318.67

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$3.76
Dividend per share
Revenue per share$8.61
Avg trading volume (30 day)$146M
Avg trading volume (10 day)$246M
Put-call ratio

Macro factor sensitivity

Growth+0.7
Credit+4.3
Liquidity+1.5
Inflation-2.2
Commodities-0.8
Interest Rates-2.7

Valuation

Dividend yield0.00%
PEG Ratio11.16
Price to sales6.14
P/E Ratio11.16
Enterprise Value to Revenue6.64
Price to book13.79

Upcoming events

Next earnings dayNovember 1, 2024
Next dividend day
Ex. dividend day

News

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research (July 3, 2025)
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Benzinga (May 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free